slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 88,411-88,440
Pages 3,683
Rows per page 30
Component
88,411-88,440 of 110,471
04
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Situation & Context1 hit
05
The slide uses a Gantt-style visualization to show the development status of various drug candidates.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
08
The slide uses a numbered list format to present the company's core strategic pillars.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
15
The chart uses a vertical axis to categorize drugs by mechanism of action (α4β7, IL-23s, TNFαs, S1P1s, JAKs) and a horizontal axis for efficacy (Pbo-adjusted clinical remission %).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
18
The slide uses a structural model of the protein complex and two dose-response curves to demonstrate efficacy and selectivity.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
20
The chart shows a biphasic exponential decay curve for three datasets.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
24
Data from GEMINI 1 study; compares Q8W and Q4W dosing regimens.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
25
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
32
Includes two charts: a dose-response curve and a scatter plot of potency vs. binding specificity.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
34
The slide uses a 2x2 grid to summarize program strengths and a timeline for catalysts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
41
The slide uses a bispecific antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
50
The slide uses a list-based format to highlight key organizational milestones and metrics.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
06
The slide uses a numbered list format to organize four distinct financial pillars.a.k.a. Brands | Investor Presentation Deck | 13 slides · a.k.a. Brands
Pitch deck Investor relations Beat · Solution1 hit
04
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
15
The slide highlights board changes, including specific appointments with shareholder support and the addition of diverse skill sets.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
12
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
17
The slide uses a before-after framework to illustrate the physiological impact of the drug.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
36
The table displays projected royalties and milestones for 2023-2026, while the right side details royalty return dates for 2029 and 2031.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
40
The slide contrasts a narrow 'dizziness' focus with a broader 'constellation of symptoms' approach for MSA patients.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
09
The chart bridges Credit Suisse equity to pro forma negative goodwill via transaction adjustments.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
02
The slide features a baseball player image, likely a metaphor for 'hitting it out of the park' or performance.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
05
The slide uses a process-flow visual to connect three key financial metrics.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
11
The slide uses a hub-and-spoke diagram to center 'Strategic Flexibility' as the outcome of four financial pillars.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Beat · Financials1 hit
05
Data source: China National Bureau of Statistics (CNBS).Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit